Coronary artery diseaseLong-Term Predictors of Mortality After Percutaneous Coronary Intervention in the Era of Drug-Eluting Stents
Section snippets
Methods
The cohort consisted of all consecutive patients from the MIG registry undergoing PCI over a 6-year period for whom prospectively collected data were available. We report complete demographic, clinical, and procedural characteristics of the total PCI population enrolled to date. Standard techniques were used for all PCIs. Choice of anticoagulation, use of glycoprotein IIb/IIIa antagonists, intravascular ultrasound, and other procedural devices were left to the discretion of the operator. Oral
Results
The cohort consisted of 10,682 consecutive patients from the MIG registry undergoing PCI (from February 2004 through November 2009) with a mean follow-up of 3.2 ± 0.5 years. Baseline demographic, lesion-related, and procedural characteristics are presented for the total cohort and then analyzed according to stent type (DES vs BMS; Tables 1 and 2).
The cohort was relatively high risk with 24% diabetics, 63% presenting with an acute coronary syndrome, 49% with complex type B2/C lesions, and 59%
Discussion
Our study represents the largest contemporary analysis of cause and timing of death after PCI in Australia. The data depict clinical outcomes from a “real-world” population of consecutive patients and thus reflect outcomes of a more challenging cohort of patients than those included in randomized controlled trials. A large proportion of patients in the MIG cohort presented with acute coronary syndromes and complex lesions, yet overall mortality remained low at extended follow-up. Our reported
References (29)
- et al.
A risk score to predict in-hospital mortality for percutaneous coronary interventions
J Am Coll Cardiol
(2006) - et al.
The foundation and launch of the Melbourne Interventional Group: a collaborative interventional cardiology projectMelbourne Interventional Group investigators
Heart Lung Circ
(2006) - et al.
Quality control activities associated with registries in interventional cardiology and surgery
Heart Lung Circ
(2011) - et al.
Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 3-year follow-up of the randomized DEDICATION (Drug Elution and Distal Protection In Acute Myocardial Infarction) trial
J Am Coll Cardiol
(2010) - et al.
A risk score to predict in-hospital mortality for percutaneous coronary interventions
J Am Coll Cardiol
(2006) - et al.
Clinical characteristics and early mortality of patients undergoing coronary artery bypass grafting compared to percutaneous coronary intervention: insights from the Australasian Society of Cardiac and Thoracic Surgeons (ASCTS) and the Melbourne Interventional Group (MIG) Registries
Heart Lung Circ
(2009) - et al.
Primary Angioplasty in Myocardial Infarction (PAMI) and the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) InvestigatorsPrediction of one-year mortality among 30-day survivors after primary percutaneous coronary interventions
Am J Cardiol
(2006) - et al.
Comparison of long-term mortality after percutaneous coronary intervention in patients treated for acute ST-elevation myocardial infarction versus those with unstable and stable angina pectoris
Am J Cardiol
(2009) - et al.
Impact of gender differences on long-term outcomes after successful percutaneous coronary intervention in patients with acute myocardial infarction
Int J Cardiol
(2010) - et al.
Is there an obesity paradox after percutaneous coronary intervention in the contemporary era?An analysis froma multicentre Australian registry
JACC Cardiovasc Interv
(2010)
Long-term outcome in patients treated with sirolimus-eluting stents in complex coronary artery lesions: 3-year results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) trial
J Am Coll Cardiol
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis
Lancet
Percutaneous coronary intervention and 30-day mortality: the British Columbia PCI risk score
Catheter Cardiovasc Interv
Long-term safety and efficacy of drug-eluting stents
Circulation
Cited by (24)
Trends, Predictors, and Outcomes Associated With 30-Day Hospital Readmissions After Percutaneous Coronary Intervention in a High-Volume Center Predominantly Using Radial Vascular Access
2020, Cardiovascular Revascularization MedicineEvaluation of the DAPT Score in Patients Who Undergo Percutaneous Coronary Intervention in England and Wales
2020, Cardiovascular Revascularization MedicineTen-year survival of patients undergoing coronary angioplasty with first-generation sirolimus-eluting stents and bare-metal stents
2020, Revista Portuguesa de CardiologiaSystematic detection of polyvascular disease combined with aggressive secondary prevention in patients presenting with severe coronary artery disease: The randomized AMERICA Study
2018, International Journal of CardiologyCitation Excerpt :The presence of asymptomatic MSAD is associated with a higher risk of recurrent symptoms or events which occur more frequently in the same arterial location as the first manifestation of atherosclerotic disease [2,6]. This has been shown also in patients who underwent percutaneous coronary revascularisation [17]. However, systematic screening of extra-coronary lesions of atherothrombosis would make sense only if they lead to a specific treatment that benefits the patient [18].
Panvascular disease – Epidemiology and prevention
2018, Cor et Vasa
The Melbourne Interventional Group acknowledges unrestricted educational grant funding from Abbott Vascular, Abbott Australasia Pty Ltd, Pharmaceuticals, Nutritionals and EAS, NSW, Australia, Astra-Zeneca, NSW, Australia, Biotronik, NSW, Australia, Boston-Scientific, NSW, Australia, Bristol-Myers Squibb, Victoria, Australia, CSL, Victoria, Australia, Johnson & Johnson, NSW, Australia, Medtronic, Melbourne, Australia, Pfizer, NSW, Australia, Schering-Plough, NSW, Australia, Sanofi-Aventis, NSW, Australia, Servier, Victoria, Australia. Dr. Duffy's work is supported by a grant from the National Health and Medical Research Council of Australia.